FIRST SINGLE-CENTER EXPERIENCE WITH LUSPATERCEPT THERAPY IN LOW-RISK MYELODYSPLASTIC SYNDROME (LR-MDS) PATIENTS WITH TRANSFUSION DEPENDENCE REFRACTORY TO ERYTHROPOIETIN THERAPY

FIRST SINGLE-CENTER EXPERIENCE WITH LUSPATERCEPT THERAPY IN LOW-RISK MYELODYSPLASTIC SYNDROME (LR-MDS) PATIENTS WITH TRANSFUSION DEPENDENCE REFRACTORY TO ERYTHROPOIETIN THERAPY

Introduction: Luspatercept is a recent breakthrough in the therapy of anemia in low-risk MDS. Methods: From January 2021 to October 2023, 44 patients (median age 77, M/F 25/19, WHO 2016 classification: MDS-RS-MLD 28, MDS-MLD -4, RARS-T 8, CMML- 0 2, 5q- + RS 2, IPSS-R: very low 2, low 33, Intermedia...

Fuld beskrivelse

Bibliografiske detaljer
Main Authors:	A. Jonasova, L. Minarik
Format:	Article
Sprog:	English
Udgivet:	Elsevier 2024-01-01
Serier:	Leukemia Research Reports
Online adgang:	http://www.sciencedirect.com/science/article/pii/S2213048924000347

Lignende værker

Experience with luspatercept therapy in patients with transfusion-dependent low-risk myelodysplastic syndromes in real-world clinical practice: exploring the positive effect of combination with erythropoietin alfa
af: Anna Jonasova, et al.
Udgivet: (2024-10-01)

EFFICACY AND SAFETY OF LUSPATERCEPT VERSUS EPOETIN ALFA IN ERYTHROPOIESIS-STIMULATING AGENT (ESA)-NAIVE PATIENTS WITH TRANSFUSION-DEPENDENT LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS): FULL ANALYSIS OF THE COMMANDS TRIAL
af: G. Garcia-Manero, et al.
Udgivet: (2024-01-01)

LUSPATERCEPT IN TRANSFUSION-DEPENDENT MYELODYSPLASTIC SYNDROMES: REAL WORLD DATA
af: Y. Gong, et al.
Udgivet: (2024-01-01)

P778: LONG-TERM UTILIZATION AND BENEFIT OF LUSPATERCEPT IN PATIENTS (PTS) WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) FROM THE MEDALIST TRIAL
af: P. Fenaux, et al.
Udgivet: (2022-06-01)

Response to luspatercept can be predicted and improves overall survival in the real‐life treatment of LR‐MDS
af: Angela Consagra, et al.
Udgivet: (2025-02-01)

S102: LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA-NAIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM THE PHASE 3 COMMANDS STUDY
af: Matteo Giovanni Della Porta, et al.
Udgivet: (2023-08-01)

Luspatercept in patients with lower-risk myelodysplastic syndromes
af: Fenaux, P, et al.
Udgivet: (2020)

Luspatercept for transfusion-dependent β-thalassemia: time to get real
af: Khaled M. Musallam, et al.
Udgivet: (2023-08-01)

VALUE OF EARLY LUSPATERCEPT USE IN LOWER-RISK MYELODYSPLASTIC SYNDROMES
af: D Valcárcel, et al.
Udgivet: (2024-10-01)

Luspatercept: A peaceful revolution in the standard of care for myelodysplastic neoplasms
af: Francesca Vinchi, et al.
Udgivet: (2024-03-01)

Luspatercept‐induced reduction in transfusion requirement in α‐thalassemia
af: Nicholas Jackson, et al.
Udgivet: (2020-07-01)

Profile of Luspatercept in the Treatment of Anemia in Adults with Non-Transfusion-Dependent β-Thalassemia (NTDT): Design, Development and Potential Place in Therapy
af: Musallam KM, et al.
Udgivet: (2023-05-01)

Current State and Challenges in Development of Targeted Therapies in Myelodysplastic Syndromes (MDS)
af: Michele Stanchina, et al.
Udgivet: (2021-04-01)

The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia
af: Julio Delgado, et al.
Udgivet: (2021-08-01)

P743: THE PIVOTAL ROLE OF GLUTAMINOLYSIS IN MYELODYSPLASTIC SYNDROME (MDS): A NOVEL STRATEGY FOR THE TARGETED THERAPY OF MDS
af: S. Okabe, et al.
Udgivet: (2022-06-01)

Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes
af: Norbert Gattermann, et al.
Udgivet: (2012-09-01)

SUCCESSFUL REDUCTION OF TRANSFUSION DEPENDENCE WITH LUSPATERCEPT IN A PATIENT WITH THALASSEMIA MAJOR: A CASE REPORT
af: Gökhan Demirci, et al.
Udgivet: (2024-12-01)

P1506: REAL-WORLD DATA ON THE USE OF LUSPATERCEPT IN GREEK PATIENTS WITH TRANSFUSION DEPENDENT THALASSEMIA
af: P. Delaporta, et al.
Udgivet: (2022-06-01)

Luspatercept's use in a patient with transfusion‐dependent beta‐thalassemia and intrathoracic extramedullary hematopoiesis (EMH)
af: Mohammed Najdat Seijari, et al.
Udgivet: (2024-05-01)

THERAPY-RELATED MYELODYSPLASTIC SYNDROMES (t-MDS) IN CHILDHOOD: THE EXPERIENCE OF THE HELLENIC STUDY GROUP FOR MDS/JMML/SAA, MEMBER OF THE EWOG-MDS/SAA WORKING GROUP
af: Loizos Petrikkos, et al.
Udgivet: (2023-12-01)

Luspatercept in Low-Risk Myelodysplastic Syndrome: A Real-World Single Institution Case Series
af: Shamis Khan, et al.
Udgivet: (2022-08-01)

Immune Complex Glomerulonephritis in a Patient with Myelodysplastic Syndrome with Ring Sideroblasts Treated with Luspatercept
af: Sigurd Delanghe, et al.
Udgivet: (2022-12-01)

Therapy related myelodysplastic syndrome (t-MDS) in childhood Acute lymphoblastic leukemia- an interesting observation
af: Kavita Gaur, et al.
Udgivet: (2022-01-01)

EFFICACY AND SAFETY OF LUSPATERCEPT IN MYELODYSPLASTIC SYNDROME/NEOPLASM WITH VERY LOW/LOW/INTERMEDIATE RISK REQUIRED TRANSFUSION: A SYSTEMATIC REVIEW AND SINGLEARM META-ANALYSIS
af: VC Monici, et al.
Udgivet: (2024-10-01)

Real‐life data of luspatercept in lower‐risk myelodysplastic syndromes advocate new research objectives
af: Bert Heyrman, et al.
Udgivet: (2024-10-01)

Population Pharmacokinetics and Exposure–Response of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With Myelodysplastic Syndromes
af: Nianhang Chen, et al.
Udgivet: (2020-07-01)

Trisomy X and myelodysplastic syndrome (MDS) with eosinophilia
af: Mohd Tohit, Eusni Rahayu, et al.
Udgivet: (2012)

The role of azacitidine in the management of myelodysplastic syndromes (MDS)
af: KS G&ouml;tze, et al.
Udgivet: (2009-10-01)

Treatment of Anemia in Transfusion-Dependent and Non-Transfusion-Dependent Lower-Risk MDS: Current and Emerging Strategies
af: Ulrich Germing, et al.
Udgivet: (2019-12-01)

PB1925: VENETOCLAX IN COMBINATION WITH AZACITIDINE OR LOW-DOSE CYTARABINE IN PATIENTS WITH HIGH-RISK MDS AND AML - EXPERIENCE OF A CZECH HAEMATOLOGY CENTRE.
af: L. Minarik, et al.
Udgivet: (2022-06-01)

Luspatercept: A New Tool for the Treatment of Anemia Related to β-Thalassemia, Myelodysplastic Syndromes and Primary Myelofibrosis
af: Eleftheria Hatzimichael, et al.
Udgivet: (2022-10-01)

Myelodysplastic Syndrome with Transfusion Dependence Treated with Venetoclax
af: Waqas Jehangir, et al.
Udgivet: (2020-01-01)

P783: SYSTEMIC THERAPY UTILIZATION AND HEMATOLOGIC OUTCOMES IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS): FINDINGS FROM A REAL-WORLD MEDICAL RECORD REVIEW STUDY IN THE US, UK, AND EUROPE (EU)
af: M. Diez-Campelo, et al.
Udgivet: (2022-06-01)

Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape
af: Daniel Karel, et al.
Udgivet: (2024-04-01)

Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)
af: Josephine Lucero, et al.
Udgivet: (2023-06-01)

Cytogenetic study of Brazilian patients with myelodysplastic syndrome (MDS)
af: Tamara Borgonovo, et al.
Udgivet: (2005-12-01)

Myelodysplastic syndromes (MDS): prognostic factors and scoring systems
af: Elizabeth Xisto Souto, et al.

PB1926: REAL-WORLD ERYTHROPOIESIS-STIMULATING AGENT (ESA) TREATMENT PATTERNS AND OUTCOMES AMONG US PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS)
af: S. Mukherjee, et al.
Udgivet: (2022-06-01)

S270: LONGER-TERM ANALYSIS OF EFFICACY OF LUSPATERCEPT VERSUS PLACEBO IN PATIENTS WITH TRANSFUSION-DEPENDENT BETA-THALASSEMIA ENROLLED IN THE BELIEVE STUDY
af: M. D. Cappellini, et al.
Udgivet: (2022-06-01)

Treatment patterns and outcomes with luspatercept in patients with lower‐risk myelodysplastic syndromes: A retrospective US cohort analysis
af: Sudipto Mukherjee, et al.
Udgivet: (2024-01-01)